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ABSTRACT
Introduction Immune checkpoint inhibitors (ICIs) have
changed the treatment landscape for multiple cancer
types. Sex plays an important role in both the development
of cancer as well as the functioning of the immune system.
Though a difference in response to immune therapy is
emerging between men and women it is unclear how this
difference affects cancer outcomes and what the potential
underlying mechanisms are for those effects. The objective
of this study is to describe the influence that sex has
on the outcomes experienced by cancer patients on ICI
therapy and to identify and analyse any knowledge gaps
in the field.
Method and analysis The framework for this
methodology was guided by the Joanna Briggs Institute
Manual for Evidence Synthesis. The search and review
will be conducted from January 2022 to June 2022.
Two independent researchers will screen titles and
abstracts followed by full-text screening for manuscript
inclusion. Full length studies published between 2010
and December 2021 found in PubMed, Cochrane, CINAHL,
and Scopus describing the influence of sex differences
on cancer outcomes in patients treated with ICIs will be
included. After data are extracted it will be summarised for
presentation.
Ethics and dissemination The findings of this scoping
review will be published in a peer-reviewed journal.
The results will be used to inform future studies on the
potential differential impacts of ICIs. All data are from
published openly accessible sources and therefore no
ethical clearance is necessary.

INTRODUCTION
Immune checkpoint inhibitors (ICIs) have
demonstrated clinical efficacy in several solid
tumour types.1 Furthermore, the role of ICIs
is going to be investigated in the neoadjuvant,
adjuvant and definitive settings in ongoing
clinical trials making it not only important to
understand how to improve patient’s abilities
to respond to treatment as it expands its role
in multiple cancer types.

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ Multidisciplinary team used during the planning and

design.
⇒ Multiple databases used to source literature.
⇒ No formal quantitative synthesis completed without

sufficient data.

Sex effects both the innate and adaptive
immune system responses, however less
than 10% of all immunology-related studies
consider sex while reporting results.2 3 Sex
hormones have been shown to influence
immune system functioning. Among patients
with autoimmune diseases medications used
to suppress immune response were more
efficacious in men than women while medications to stimulate response are more efficacious in women.4 Sex plays an important role
in the pathogenesis and prognosis of several
cancer types. For a vast majority of cancer
types, men have a higher predisposition of
developing cancer than women. Specifically,
men have a twofold higher risk of mortality
from all malignant cancer types than women
(after excluding sex-
specific cancers such
as breast and prostate).5 Women are under-
represented in randomised clinical trials
(RCTs) for immunotherapies. In a meta-
analysis of phase II and III immunotherapy,
RCTs observed improvement in overall
survival and progression free survival for both
men and women, but the benefit was much
larger among men than in women.6–8 ICIs
depend on antigen presentation occurring.
However, women sometimes have a lower
tumour mutation burden.9 Another study
discovered that in female antigens are not as
frequently presented to the immune system
by the major histocompatibility complex.10
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Altogether, this may explain why ICIs become less effectual.11 Since evidence suggests that men and women
respond differently to therapies, it is important to explore
these differences to redefine clinical decision making
and improve outcomes for all patients with cancer. A first
step of that discovery is through an examination of the
current evidence.
The purpose of this scoping review is to describe the
influence that sex has on the outcomes experienced by
patients with cancer on ICI therapy and to identify and
analyse any knowledge gaps in the field.
METHODS
Protocol design
This scoping review will be conducted according to
the Joanna Briggs Institute methodology for scoping
reviews which is based predominately on the protocols
established by Arksey and O’Malley but includes the
revisions suggested by Levac et al and Peters et al.12–16
The review will follow six steps including: (1) defining
the research question, (2) identifying relevant studies,
(3) study selection, (4) charting the data, (5) collating,
summarising, and reporting the results, and (6) consultation. Reporting of findings will be conducted according
to Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines using the PRISMA
extension for scoping reviews (PRISMA-ScR) checklist.17
Stage 1: identifying the research question
The central research question for this review is: what
influence does sex play on the outcomes experienced
by patients with cancer on immune checkpoint inhibitor
therapy? Outcomes are being left purposefully vague so as
to capture as much information as possible. All outcome
data will then be categorised later in the ‘collating,
summarising and reporting’ stage. Also to be examined is
whether the ICI therapy is monotherapy, dual therapy or
combination with other therapies.

AND
“Sex”[MeSH Terms] OR “Sex Characteristics”[MeSH
Terms] OR “Sex Factors”[MeSH Terms] OR “Male”[MeSH
Terms] OR “Female”[MeSH Terms] OR “sex-related” OR
“gender-related” OR “sex differences”
AND
“Immune checkpoint inhibitor” OR “anti-
PD-
1” OR
“anti-
CTLA-
4” OR “anti-
PD-
L1” OR “Immune checkpoint blockade” OR “REGN2810” OR “ Cemiplimab” OR
“BMS-936559” OR “MSB0010718C” OR “avelumab” OR
“MEDI4736” OR “durvalumab” OR MPDL3280A” OR
“atezolizumab” OR “MK-3475” OR “pembrolizumab” OR
“BMS-936558” OR “nivolumab”
Stage 3: study selection
Inclusion criteria
Types of participants
This scoping review will only include adult patients
aged 18 years or olderbeing treated with ICIs for those
cancers for which the Food and Drug Administration has
approved the use of ICIs as treatment as of December
2020.
Concept
The review will focus on peer-reviewed publications that
seek to clarify the influence of sex on the outcomes of
ICIs.
Context
The review will include both institutional and community
care settings.
Types of sources
All peer-
reviewed publications published since 2010
through December 2021.

Stage 2: identifying relevant studies, search strategy
The search strategy for this review is the result of prior
research in the adjacent fields of prostate cancer, lung
cancer, and immunotherapy as well as the strategies
recommended by Tawfik et al for adapting searches
according to database.18 An experienced search librarian
was also consulted. We will conduct a search of PubMed,
CINAHL, Cochrane Library and Scopus.
We will conduct a search using the following keywords:
cancer, “neoplasms”, “immune checkpoint inhibitors”,
“sex”, “sex factors”, and associated mesh terms. These
terms will be combined with the Boolean operators
“AND” and “OR”.
The initial search will be in PubMed. A similar search
will be used for Cochrane which also uses MeSH terms.
Only key words will be used for SCOPUS. CINAHL uses
Subject terms in lieu of MeSH terms.
The search string for the PubMed database is as follows:
cancer* OR (“Neoplasms”[Mesh])

Exclusion criteria
The search will be restricted to articles and reports
published in English.
Opinion pieces.
Letters to the editor.
Studies identified by these terms which satisfy the inclusion criteria will be considered for the initial title and
abstract screening. The search string will be adapted for
other databases as required. The reference lists of all
included articles will be searched for additional studies.
As required by good practice, the completed strings for
each database will be included in the published scoping
review.
If further information is required, we will contact
authors of the publications as appropriate.
The research team will use Endnote V.X9 software
for managing imported references and removing duplications. The title, abstracts and keywords for all articles
will be screened by two independent reviewers from
the research team to determine whether they satisfy the
inclusion criteria, see Inclusion Assessment Form, online
supplemental material. Each article will be considered by
at least two researchers for inclusion and any discrepancies will be will be discussed.
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Articles satisfying the initial screen will undergo full
text screening by two independent researchers from the
research team. An important part of full-text screening is
to discern the inclusion of sex comparison, which my only
occur through covariate inclusion but still offer comparison between the sexes. Disagreements of study eligibility
will be resolved through discussion with a senior member
of the research team.

Contributors Study concept and design: ALS, NN, SS, DSL, AB-M, JMJ, MLB and
GL-Y. Protocol writing and review: ALS, NN and GL-Y.
Funding This work was supported, in part, by the NCI Cancer Center Support Grant
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Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in
the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not applicable.
Provenance and peer review Not commissioned; externally peer reviewed.

Stage 4: charting the data
Extraction of the results
Three members of the research team will participate
in the data extraction process. From each article, the
following information will be extracted: author, year of
publication, title, ICI, study type/design, study population, primary objective(s) and outcome(s)/summary, see
Extraction Charting Form, online supplemental material.
Patient and public involvement
This research will be done without patient involvement.
Patients are neither invited to comment on the study
design nor consulted to develop patient-relevant outcomes
nor to interpret nor disseminate the results. Sex differences in cancer outcomes are known to be important to
patients. Any future studies deriving from this work will
include patient involvement to help to ensure that, from
a patient’s perspective, the outcomes are relevant.

Supplemental material This content has been supplied by the author(s). It has
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been
peer-reviewed. Any opinions or recommendations discussed are solely those
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and
responsibility arising from any reliance placed on the content. Where the content
includes any translated material, BMJ does not warrant the accuracy and reliability
of the translations (including but not limited to local regulations, clinical guidelines,
terminology, drug names and drug dosages), and is not responsible for any error
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits
others to copy, redistribute, remix, transform and build upon this work for any
purpose, provided the original work is properly cited, a link to the licence is given,
and indication of whether changes were made. See: https://creativecommons.org/
licenses/by/4.0/.
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Stage 6: consultation
We have purposefully included researchers from multiple
disciplines in our group (pharmacy, medicine and epidemiology). The diversity of the group brings fresh views
and broad experiences to the analysis of the literature. At
the end of the study, a final consultation will take place
so the results of the study can have the context of clinical
practice knowledge.
Ethics and dissemination
The scoping review as indicated earlier is based on openly
accessible published material and is therefore not subject
to an ethical review board. The findings of this scoping
review will be published in a peer-reviewed journal. The
results will be used to inform future studies on the potential differential impacts of ICIs.
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Stage 5: collating, summarising and reporting
Presentation of our results
Our search results will be presented in a PRISMA flowScR checklist. The
chart and an appended PRISMA-
extracted data will be presented under the following
headings: author, year of publication, study type, study
population, primary objective(s) and outcome(s).
A full summary of evidence including an overview
of concepts and types of evidence available as well as a
discussion of limitations and our conclusions will follow.
Analyses of mono and combination therapies will be
conducted separately when possible. We will identify gaps
in the literature and highlight the implications for future
research.
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